Compare MATX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATX | IMVT |
|---|---|---|
| Founded | 1882 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.3B |
| IPO Year | N/A | N/A |
| Metric | MATX | IMVT |
|---|---|---|
| Price | $158.32 | $25.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $150.00 | $30.78 |
| AVG Volume (30 Days) | 325.5K | ★ 1.5M |
| Earning Date | 02-24-2026 | 02-06-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ 10.58 | N/A |
| EPS | ★ 13.11 | N/A |
| Revenue | ★ $3,382,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $86.97 | $12.72 |
| 52 Week High | $169.20 | $27.92 |
| Indicator | MATX | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 48.62 |
| Support Level | $158.23 | $23.90 |
| Resistance Level | $163.78 | $27.92 |
| Average True Range (ATR) | 4.87 | 1.34 |
| MACD | -1.41 | -0.05 |
| Stochastic Oscillator | 28.28 | 46.23 |
Matson Inc is engaged in providing ocean transportation and logistics services. The business segments of the company are Ocean Transportation which provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific, and Logistics segment which offers long haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.